Aspira Women’s Health Announces Appointment of Dr. Sandra Milligan as Interim CEO
Aspira Women's Health (NASDAQ: AWH) announced that CEO Nicole Sandford will step down immediately for personal reasons, with Dr. Sandra Milligan, the company's President, appointed as interim CEO. During Sandford's tenure, the company launched the OvaWatch multivariate assay for ovarian cancer detection and received a $10 million award from the Advanced Research Projects Agency for Health to complete their endometriosis detection product. Sandford will remain as a consultant to ensure a smooth transition while the company conducts a nationwide search for a permanent CEO. The Board praised Sandford's contributions in stabilizing the business and building a strong team for future growth.
Aspira Women's Health (NASDAQ: AWH) ha annunciato che l'amministratore delegato Nicole Sandford si dimetterà immediatamente per motivi personali, con la Dr.ssa Sandra Milligan, Presidente dell'azienda, nominata amministratore delegato ad interim. Durante il mandato di Sandford, l'azienda ha lanciato il test multivariato OvaWatch per la rilevazione del cancro ovarico e ha ricevuto un finanziamento di 10 milioni di dollari dall'Advanced Research Projects Agency for Health per completare il loro prodotto per la rilevazione dell'endometriosi. Sandford rimarrà come consulente per garantire una transizione fluida mentre l'azienda conduce una ricerca a livello nazionale per un amministratore delegato permanente. Il Consiglio ha elogiato i contributi di Sandford per aver stabilizzato l'azienda e costruito un team forte per la crescita futura.
Aspira Women's Health (NASDAQ: AWH) anunció que la CEO Nicole Sandford dejará su puesto de inmediato por razones personales, siendo la Dra. Sandra Milligan, presidenta de la compañía, nombrada como CEO interina. Durante el mandato de Sandford, la empresa lanzó el ensayo multivariado OvaWatch para la detección del cáncer de ovario y recibió un premio de 10 millones de dólares de la Agencia de Proyectos de Investigación Avanzada en Salud para completar su producto de detección de endometriosis. Sandford permanecerá como consultora para garantizar una transición sin problemas mientras la empresa realiza una búsqueda a nivel nacional para un CEO permanente. La Junta elogió las contribuciones de Sandford por estabilizar el negocio y construir un equipo sólido para el crecimiento futuro.
Aspira Women's Health (NASDAQ: AWH)는 CEO인 니콜 샌포드가 개인적인 이유로 즉시 사임할 것이라고 발표했으며, 회사의 회장인 산드라 밀리건 박사가 임시 CEO로 임명되었습니다. 샌포드의 재임 동안, 회사는 난소암 검출을 위한 OvaWatch 다변량 검사를 출시했으며, 내막증 검출 제품 완료를 위해 건강을 위한 고급 연구 프로젝트 기관으로부터 1000만 달러의 지원금을 받았습니다. 샌포드는 부드러운 전환을 보장하기 위해 컨설턴트로 남아 있으며, 회사는 영구 CEO를 위한 전국적인 검색을 진행하고 있습니다. 이사회는 샌포드가 비즈니스를 안정시키고 미래 성장을 위한 강력한 팀을 구축한 기여를 칭찬했습니다.
Aspira Women's Health (NASDAQ: AWH) a annoncé que la PDG Nicole Sandford démissionnera immédiatement pour des raisons personnelles, et que Dr. Sandra Milligan, présidente de l'entreprise, a été nommée PDG par intérim. Pendant le mandat de Sandford, l'entreprise a lancé le test multivarié OvaWatch pour la détection du cancer de l'ovaire et a reçu une subvention de 10 millions de dollars de l'Agence des projets de recherche avancée en santé pour compléter son produit de détection de l'endométriose. Sandford restera en tant que consultante pour garantir une transition en douceur tandis que l'entreprise mène une recherche à l'échelle nationale pour un PDG permanent. Le conseil d'administration a salué les contributions de Sandford pour stabiliser l'entreprise et construire une équipe solide pour la croissance future.
Aspira Women's Health (NASDAQ: AWH) gab bekannt, dass die CEO Nicole Sandford aus persönlichen Gründen mit sofortiger Wirkung zurücktritt. Die Präsidentin des Unternehmens, Dr. Sandra Milligan, wurde interimistisch zur CEO ernannt. Während Sandfords Amtszeit hat das Unternehmen den OvaWatch Multivariate Assay zur Erkennung von Eierstockkrebs eingeführt und einen Preis von 10 Millionen Dollar von der Advanced Research Projects Agency for Health erhalten, um ihr Produkt zur Erkennung von Endometriose zu vervollständigen. Sandford bleibt als Beraterin, um einen reibungslosen Übergang zu gewährleisten, während das Unternehmen eine landesweite Suche nach einem permanenten CEO durchführt. Der Vorstand lobte Sandfords Beiträge zur Stabilisierung des Unternehmens und zum Aufbau eines starken Teams für zukünftiges Wachstum.
- Received $10 million award for endometriosis detection product development
- Successfully launched OvaWatch multivariate assay for ovarian cancer detection
- Maintaining continuity with departing CEO staying as consultant
- Unexpected CEO departure creates leadership uncertainty
- Need for nationwide CEO search may delay strategic decisions
CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transition
AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira’s President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford’s departure will be effective immediately. She will remain as a consultant to ensure a seamless transition.
“The Board thanks Nicole for the outstanding work she has done in stabilizing the business, building a first-class team, and putting the company on solid footing for the next phase of growth,” said Ms. Jannie Herchuk, Chairwoman of the Board at Aspira. “During her tenure as CEO, Aspira launched its OvaWatch multivariate assay, a significant expansion of our commercial ovarian cancer portfolio, and received a
“Sandy Milligan has a deep understanding of Aspira’s technology and vision and is well-positioned to oversee the continued execution of the Company’s long-term growth strategy as we search for a permanent successor,” Ms. Herchuk continued.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of
Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.
Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as “designed to,” “expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 10-K, for the fiscal year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira’s expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company’s assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Relations Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com
FAQ
Why is Nicole Sandford stepping down as CEO of Aspira Women's Health (AWH)?
Who is the interim CEO of Aspira Women's Health (AWH)?
What major achievements occurred during Nicole Sandford's tenure at AWH?
What is Aspira Women's Health's (AWH) plan for finding a new permanent CEO?
